Lataa...
Seven‐year safety and efficacy with velaglucerase alfa for treatment‐naïve adult patients with type 1 Gaucher disease
Velaglucerase alfa is a human β‐glucocerebrosidase approved for Gaucher disease type 1 (GD1) treatment. This report summarizes the 7‐year experience of the now‐completed phase I/II and extension studies of adult GD1 patients who received velaglucerase alfa. Ten patients who completed the 9‐month, ph...
Tallennettuna:
| Julkaisussa: | Am J Hematol |
|---|---|
| Päätekijät: | , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5033020/ https://ncbi.nlm.nih.gov/pubmed/25903392 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24040 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|